Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients
S Petrovski, CEI Szoeke, NC Jones, MR Salzberg, LJ Sheffield, RM Huggins, TJ O'Brien
Neurology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2010
Awarded by NHMRC
Mr. Petrovski reports no disclosures. Dr. Szoeke has received speaker honoraria from Pfizer Inc, Lundbeck Inc., and Mayne Pharma; serves as a consultant for the Commonwealth Science and Industry Research Organisation; and receives research support from the Australian NHMRC, the National Ageing Research Institute (Melbourne Health), the Epilepsy Society of Australia, the Royal Australasian College of Physicians, the Alzheimer's Association of Australia, and the Scobie and Claire Mc Kinnon Foundation. Dr. Jones reports no disclosures. Dr. Salzberg receives research support from the Australian NHMRC and beyondblue (Australian National Depression Initiative). Dr. Sheffield has filed a patent re: A Diagnostic Assay. Dr. Huggins has received research support from the Australian NHMRC. Prof. O'Brien serves on the editorial boards of Epilepsia, the Journal of Clinical Neuroscience, and Epilepsy and Behavior; has received speaker honoraria from Janssen and sanofi-aventis 2009; and receives research support from UCB, Abbott Laboratories, Janssen, the Australian NHMRC, the Epilepsy Research Foundation, NARSAD, and the Royal Melbourne Hospital Neuroscience Foundation.Supported by the NHMRC (400088 and 566843 to T.J.O., M.S.,and N.J.), RMH Home Lottery Research Fund of Melbourne Health (chief investigator S. P.), Pfizer Inc and the Victor Hurley (chief investigator C. S.), and the Royal Melbourne Hospital Neuroscience Research Foundation (chief investigator T.J.O.). BioGrid Australia (formerly Bio21: MMIM) provided server space to house the databases, implemented an interface to facilitate data entry, and funded support staff to enter the data.